Journal article
Glycoprotein IIb/IIIa Receptor Therapy in Percutaneous Coronary Intervention and Non-ST-Segment Elevation Acute Coronary Syndromes
Abstract
In addition to efficacy and safety, cost is an important determinant of the use of glycoprotein IIb/IIIa (GPIIb/IIIa) therapy in patients with acute coronary syndromes (ACS) or undergoing percutaneous coronary intervention (PCI).In PCI, the average procurement cost of GPIIb/IIIa therapy ranges from $US400 to $US1500 (1999 values) per patient treated, depending on agent, dose and duration of infusion. Prospective economic substudies with …
Authors
Hillegass WB; Newman AR; Raco DL
Journal
PharmacoEconomics, Vol. 19, No. 1, pp. 41–55
Publisher
Springer Nature
Publication Date
1 2001
DOI
10.2165/00019053-200119010-00003
ISSN
1170-7690